Malignant pleural mesothelioma

Annals of Oncology

Volumn 9, Issue 2, 1998, Pages 139-149

  Baas, P ^a   Schouwink, H ^a   Zoetmulder, F A N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Asbestos; Chemotherapy; Epidemiology; Malignant mesothelioma; Photodynamic therapy; Radiation therapy; Surgery

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN; VINBLASTINE; VINCRISTINE;

ASBESTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; ENVIRONMENTAL EXPOSURE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 0031938756     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008239116237     Document Type: Review

References (151)

1. Wagner E. Das tuberkelahnliche Lymphadenoom. Arch Heilk 1870; 11: 495-525.
2. Klemperer P and Rabin C B Primary neoplasms of the pleura. A report of five cases. Arch Pathol 1931; 11: 385-412.
3. Saccone A and Coblenz A. Endothelioma of the pleura. Am J Clin Pathol 1943; 13: 188-207.
4. Gloyne SR. Two cases of squamous carcinoma of the lung occurring in asbestosis. Tubercl 1935; 17: 5-10.
5. Wedler HW. Uber den Lungenkrebs bei Asbestose. Dtsch Arch Klin Med 1943; 191: 189-209.
6. Cartier P. Abstract of discussion. Arch Indust Hyg Med 1952; 5: 262.
7. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-71.
8. IUCC. Report and recommendations of the working group on asbestos and cancer. Ann NY Acad Sci 1965; 132: 706-21.
9. Walker AM, Loughlin JE, Friedlander ER et al. Projections of asbestos related disease 1980-2009. J Occup Med 1983; 25: 409-25.
10. Spirtas R. Beebe GW, Connelly RR et al. Recent trends in mesothelioma incidence in the United States. Am J Ind Med 1986; 9: 397-407.
11. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-9.
12. Burdorf A, Barendregt JJ, Swuste PHJJ. Heederik DJJ. Increasing incidence of mesothelioma in the future by professional exposure to asbestos in the past. Dutch J Med 1997; 141: 1093-8 (English Summary).
13. Hillerdal G. Malignant mesothelioma in 1982: Review of 4710 published cases. Br J Dis Chest 1983; 77: 321-39.
14. McDonald JC. Malignant mesothelioma in North America. Cancer 1980; 46: 1650-6.
15. Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med 1996; 30: 252-66.
16. Vianna NJ, Poln AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978; 1: 1061-3.
17. Epler GR, Gerald MXF, Gaensler AE, Carrington CB. Asbestos related disease from household exposure. Respiration 1980; 39: 229-40.
18. Chen W, Mottel NK. Malignant mesothelioma with minimal asbestos exposure. Human Pathol 1978; 9: 253-8.
19. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 46: 2736-40.
20. Churg A. Chrysotile, tremolite and malignant mesothelioma in man. Chest 1988; 93: 621-8.
21. Hughes JM, Weill H. Asbestos exposure-quantitative assessment of risk. Am Rev Resp Dis 1986; 133: 5-13.
22. Grundy GW, Miller RW. Malignant mesothelioma in childhood: Report of 13 cases. Cancer 1972; 30: 1216-8.
23. Kane MJ, Chahinian AP, Holland JF. Malignant mesothelioma in young adults. Cancer 1990; 65: 1449-55.
24. Chahinian AP, Pajak TF, Holland JF et al. Diffuse malignant mesothelioma. Ann Int Med 1982; 96: 746-55.
25. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax 1997; 52: 507-12.
26. Stock RJ, Fu YS, Carter JR. Malignant peritoneal mesothelioma following radiotherapy for seminoma of the testis. Cancer 1979; 44: 914-9.
27. Gilks B, Hegedus C, Freeman H et al. Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 1988; 61: 2019-21.
28. Babcock TL, Powell DH, Bothwell RS. Radiation induced peritoneal mesothelioma. J Surg Oncol 1976; 8: 369-72.
29. Maurer R, Egloff B. Malignant peritoneal mesothelioma after cholangiography with thoracotrast. Cancer 1975; 36: 1381-5.
30. Dahlgren S. Effects of locally deposited colloidal thorium dioxide. Ann NY Acad Sci 1967; 145: 786-90.
31. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: A review of 123 patients. Cancer 1982; 49; 2431-5.
32. Hirch A, Brochard P, DeCremoux H et al. Features of asbestos exposed and unexposed mesothelioma. Am J Indus Med 1982; 3: 413-22.
33. Baris YI, Sahin AA, Ozesmi M et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 1978; 33: 181-92.
34. Baris YI, Saracci R, Simonato L et al. Malignant mesothelioma and radiological chest abnormalities in two villages in central Turkey. Lancet 1981; i (8227): 984-7.
35. Lilis R. Fibrous zeolites and endemic mesothelioma in Cappadocia, Turkey. J Occup Med 1981; 23: 548-50.
36. Sabastien P, Gaudichet A, Bignon J, Baris YI. Zeolite bodies in human lungs from Turkey. Lab Invest 1981; 44: 420-5.
37. Rohl AN, Langer AM, Moncure G et al. Endemic pleural disease associated with exposure to mixed fibrous dust in Turkey. Science 1982; 216: 518-20.
38. Roviaro GC, Sartori f, Calabro F, Varoli F. The association of pleura mesothelioma and tuberculosis. Am Rev Resp Dis 1982; 126: 569-71.
39. Stanton MF, Wrench C. Mechanisms of mesothelioma induction with asbestos and fibrous glass. J Nath Cancer Inst 1972; 48: 797-821.
40. Suzuki Y. Carcinogenic and fibrinogenic effects of zeolites: Preliminary observations. Environ Res 1982; 27: 433-45.
41. Peterson JT, Greenberg SD, Buffler PA. Non asbestos related malignant mesothelioma. Cancer 1984; 54: 951-60.
42. Churg J, Rosen SH, Moolton S. Histological characteristics of mesothelioma associated with asbestos. Ann NY Acad Sci 1965; 132: 614-22.
43. Corson JM. Pathology of malignant mesothelioma. In Antman K, Aisner J (eds): Asbestos related malignancy 1986; chapter 9: 179-99.
44. Schouwink JH, Baas P, Van Zandwijk N et al. Lymphnodes are frequently involved in patients with malignant pleural mesothelioma. Abstr Europ Resp Soc 1997; 395s.
45. Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 1996; 109: 109-14.
46. Antman K, Cohen S, Dimitrov NV et al. Malignant mesothelioma of the tunica vaginalis testis. J Clin One 1984; 3: 447-51.
47. Talerman A, Montera JR, Chilcote RR et al. Diffuse malignant peritoneal mesothelioma in a 13 year old girl. Am J Surg Pathol 1985; 9: 73-80
48. Geary WA, Mills SE, Frierson Jr HF, Pope TL. Malignant peritoneal meso-thelioma in childhood with long-term survival. Am J Clin Path 1991; 95: 493-8.
49. Dardick I, Jabi M, McCaughey WT et al. Diffuse epithelial mesothelioma: A review of the ultrastructural spectrum. Ultrastruct Pathol 1987; 11: 503-33.
50. Hammer SP. The pathology of benign and malignant pleural disease. Chest Surg Clin North Am 1994; 4 (3): 405-30.
51. Schouwink JH, Korse CM, Bonfrer JGM, Baas P. Cyfra 21-1 a useful marker in malignant mesothelioma. XXIV Meet Int Soc Onco-development Biol Med 1996; 98 and submitted to Chest (Abstr).
52. Gibas Z, Frederick P, Antman KH et al. Chromosome changes in malignant mesothelioma. Cancer Gent Cytogen 1986; 20: 191-201.
53. Popescu NC, Chahinian AP, DiPaolo JA. Nonrandon chromosome alterations in human malignant mesothelioma. Cancer Res 1988; 48: 142-7.
54. Mor O, Yaron P, Huszar M et al. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997; 16: 9-13.
55. Wadler S, Chahinian AP, Slater W et al. Cardiac abnormalities in patients with diffuse pleural malignant mesothelioma. Cancer 1986; 58: 2744-50.
56. Maasilta P, Vehmas T, Kivisaari L et al. Correlations between findings at computer tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma. Eur Resp J 1991; 4: 952-4.
57. Sugarbaker DJ, Strauss GM, Lynch TJ et al. Node staging has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993; 11: 1172-8.
58. Lorigan JG, Libshitz HI. MR imaging of malignant pleural mesothelioma. J Comput Assist Tomogr 1989; 13: 617-20.
59. Patz EF, Shaffer K, Piwnica-Worms DR et al. Malignant pleural mesothelioma: Value of CT and MRI imaging in predicting resectability. A J R 1992; 159: 961-6.
60. Conlon KC, Rusch VW, Gillern S. Laparoscopy: An important tool in the staging of malignant pleural mesothelioma. Ann Surg Oncol 1996; 3: 489-94.
61. Bury Th, Paulus P, Dowlati A et al. Evaluation of pleural diseases with FDG-PET imaging: A prelimanary report. Thorax 1997; 52: 187-9.
62. Teirstein AS, Chahinian AP, Goldsmith SJ, Sorek M. Gallium scanning in differentiating malignant from benign asbestos related pleural disease. Am J Ind Med 1986; 9: 487-94.
63. Ruffie P, Felt R, Minkin S et al. Diffuse malignant mesothelioma of the pleura. J Clin Oncol 1989; 7: 1157-68.
64. Martensson, Hagmar B, Zettergren L. Diagnosis and prognosis in malignant pleural mesothelioma: A prospective study. Eur J Resp Dis 1984; 656: 169-78.
65. International Mesothelioma Interest Group. A new staging system for malignant mesothelioma. Chest 1995; 108: 1122-6.
66. Baas P, Murrer L, Zoetmulder FAN et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997; 76: 819-26.
67. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients the Dana-Farber Institute and Brigham and Women's hospital experience over two decades. J Clin Oncol 1988; 6: 147-53.
68. Alberts AS, Falkson G, Gaedhals L et al. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527-35.
69. Chahinian AP, Pajak TF, Holland JF, Green G. Adverse prognostic significance of thrombocytosis in patient with malignant mesothelioma. Proc Am Assoc Cancer Res 1984; 25: 161.
70. Antman KH, Blum RH, Greenberger JS et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68: 356-62.
71. Van Gelder T, Damhuis RAM, Hoogsteden HC. Prognostic factors and survival in malignant mesothelioma. Eur Respir J 1994; 7: 1035-8.
72. Boutin C.Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2 prognosis and staging. Cancer 1993; 72: 394-404.
73. De Prangher Manzini V, Brollo A, Franceschi S et al. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993; 72: 410-7.
74. Manzini VDP, Brollo A, Franceschi S et al. Prognostic factors of MM of the pleura. Cancer 1993; 72: 410-7.
75. Pluygers E, Baldewyns. Tissue polypeptide antigen (TPA) as a biomarker of the mesothelial cell and of mesothelioma. Eur Respir Rev 1993; 3 (11): 47-9.
76. Corson JM. Pathology of malignant mesothelioma. In Antman K, Aisner J (eds): Asbestos-Related Malignancy. Orlando, FL: Grune & Stratton 1987; 179-99.
77. Dejmek A, Hjerpe A. Carcinoembryonic antigen like reactivity in malignant mesothelioma. Cancer 1994; 73: 464-9.
78. Boersma A, Degand P, Biserte G. Hyaluronic acid and the diagnosis of pleural mesothelioma. Bull Europ Physiopath Resp 1980; 16: 41-5.
79. Gottener A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma: Prognostic implications. Chest 1991; 100: 1003-6.
80. Pass HI and Progebniak HW. Malignant pleural mesothelioma. In Current Problems in Surgery. St. Louis: Mosby 1993; Vol 30: 973-4.
81. Chahinian AP, Holland JF. Treatment of diffuse malignant mesothelioma: A review. Mt Sinai J Med 1978; 45: 54-67.
82. Law MR, Gregor A, Hudson ME et al. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax 1984; 39: 255-9.
83. Sugarbaker DJ, Heher EC, Lee TH et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991; 102: 10-5.
84. Rusch VW, Piantidosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: A lung cancer study group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
85. Martini N, McCormick PM, Bains MS et al. Pleural mesothelioma. Ann Thorac Surg 1987; 40: 113-20.
86. Faber LP. Current controversies in thoracic surgery. Philadelphia: WB Saunders 1986; 80.
87. Hilaris BS, Nori D, Kwong E et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. J Radiat One Biol Phys 1984; 10: 325-31.
88. Wanebo HJ, Martini N, Melamed MR et al. Pleural mesothelioma. Cancer 1976; 38: 2481-8.
89. Worn H. Moglichkeiten und ergebnisse der chirurgischen behandlung des malignen pleuramesotheliomas. Thoraxchirurgie 1974; 4 (22): 391-3.
90. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuro-pneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 1976; 31: 15-24.
91. DaValle MJ, Penfield-Faber L, Kittle CF, Jensik RJ. Extrapleural pneumonectomy for diffuse malignant mesothelioma. Ann Thorac Surg 1986; 42: 612-8.
92. Baldini EH, Recht A, Strauss GM et al. Patterns of failure after trimodality therapy for malignant mesothelioma. Ann Thorac Surg 1997; 63: 334-8.
93. Rice TW, Adelstein DJ, Kirby TJ et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1994; 58: 24-9.
94. Pass HI, Delaney T, Tochner Z et al. Intrapleural photodynamic therapy: Results of a phase I trial. Ann Surg Oncol 1994; 1: 28-37.
95. Ris HB, Altermatt HJ, Nachbur B et al. Intraoperative photodynamic therapy with mTHPC for chest malignancies. Las Surg Med 1996; 18: 39-45.
96. Warloe T, Heyerdahl H, Peng Q et al. Photodynamic therapy of malignant mesothelioma of the pleura. SPIE 1994; 2371: 166-70.
97. Takita H, Mang TS, Loewen GM et al. Operation and intracavitary photodynamic therapy for malignant mesothelioma: A phase II study. Ann Thorac Surg 1994; 58: 995-8.
98. Markman M, Kelsen D. Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Reg Cancer Treat 1989; 2: 49-53.
99. Vidai Jove J, Sweatman TW, Israel M et al. A curative approach to malignant peritoneal mesothelioma: case report and review of the literature. Res Cancer Treat 1991; 3: 269-74.
100. Gordon W, Antman KH, Greenberger JS et al. Radiation therapy in the management of patients with malignant mesothelioma. Int J Radiat Oncol Biol Phys 1981; 8: 19-25.
101. Eschwege S, Schlienger M. La radiotherapie des mesotheliomes pleuraux malins, A propos de 14 cas irradies a doses elevees. J Radiol Electrol (Paris) 1973; 54: 255-9.
102. Kutcher GJ, Kestler RT, Greenbladt D et al. Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 1987; 13: 1747-52.
103. Hilaris BS, Nori D, Kwon E et al. Pleurectomy and intraoperative brachytherapy and postoperative irradiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 1984; 10: 325-31.
104. Mbidde EK, Harland SJ, Calvert AH, Smth IE. Phase II trial of carboplatin (JM8) in the treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18: 284-5.
105. Vogelzang NJ, Goutsou M, Graziano S. Carboplatin in malignant mesothelioma: A phase II study of CALGB. Proc Am Soc Clin Oncol 1989; 8: 321.
106. Raghaven D, Gianoutsos P, Bishop J et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151-4.
107. Mintzer DM, Kelsen D, Frimmer D et al. Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985; 69: 711-2.
108. Zidar BL, Goldberg R, Guy J. A phase II evaluation of cisplatinum in unresectable diffuse malignant mesothelioma. Proc Am Soc Clin Oncol 1987; 6: 125.
109. Lerner JH, Schoenfeld DA, Martin A et al. Malignant mesothelioma. Proc Am Assoc Cancer Res 1981; 22: 527.
110. Chahinian AP, Pajak TF, Holland JF et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746-55.
111. Sorensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant mesothelioma. Cancer Treat Rep 1985; 69: 1431-2.
112. Alberts AS, Falkson G, Van Zyl L. Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988; 80: 698-700.
113. Mattson K, Van Breukelen FJM, Tammilehto L et al. 4-Epidoxorubicin in mesothelioma: A phase II study for the EORTC Lung Cancer Cooperative Group. Lung Cancer 1988; 4 (Suppl): A138.
114. Magri MD, De Giovanni D, Serra C et al. Epirubicin treatment of mesothelioma: A phase II study. Proc Am Soc Clin Oncol 1988; 7: 207.
115. Mattson K, Giaccone G, Kirkpatrick A et al. Epirubicin in malignant mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. J Clin Oncol 1992; 10: 824-8.
116. Icli F, Karaoguz H, Hasturk S et al. Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 1996; 15: 207-13.
117. Kelsen DP, Bajorin D, Mintzer D. Phase II trial of mitomycin in malignant mesothelioma. Proc Am Soc Clin Oncol 1985; 4: 146.
118. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987; 71: 857-8.
119. Eisenhauer EA, Evans WK, Raghaven D et al. Phase II study of mitoxantrone in patient with malignant mesothelioma. A National Cancer Institute of Canada Clinical Trial Group study. Cancer Treat Rep 1986; 70: 1029-30.
120. Van Meerbeeck J, Debruyne C, Zandwijk N van et al. Placlitaxel for malignant mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74: 961-3.
121. Martensson G, Sorenson S. A phase II study of vincristine in maliganat mesothelioma - a negative report. Cancer Chemother Pharmacol 1989; 24: 133-4.
122. Jones DEC, Silver D. Peritoneal mesothelioma. Surgery 1979; 86: 556-60.
123. Boutin C, Irisson M, Guerin JC et al. Phase II trial of videsine in malignant pleural mesothelioma. Cancer Treat Rep 1987; 71: 205-6.
124. Samoud T, Postmus PE, Pottelsberghe C van et al. Etoposide in malignant mesothelioma: Phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997 (Submitted).
125. Planting A, Schellens JHM, Goey SH et al. Weekly high dose cisplatinum in malignant pleural mesothelioma. Ann Oncol 1994; 5: 373-4.
126. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956-60.
127. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 1991; 28: 319-30.
128. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 1996; 14: 1007-17.
129. Henss H, Fiebig HH, Schildge J et al. Behandlung des fort-geschrittenen Pleuramesothelioms mit cisplatin und doxorubicin. Cancer Res Clin Oncol 1986; 111 (Suppl): 67.
130. Henss H, Fiebig HH, Schildge J et al. Phase II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988; 11: 118-20.
131. Ardizzoni A, Rosso R, Palma M et al. Cisplatin and adriamycin in the treatment of malignant pleural mesothelioma. A phase II trial. Lung Cancer 1988; 4 (Suppl): A136.
132. Chahinian AP, Norton L, Holland JF et al. Experimental and clinical activity of mitomycin C and cis-diaminedichloroplatinum in malignant mesothelioma. Cancer Res 1984; 44: 1688-92.
133. Chahinian AP, Antman KH, Aisner J et al. Cisplatin with adriamycin or mitomycin for malignant mesothelioma: A randomized phase II trial. Proc Am Soc Clin Oncol 1987; 6: 183.
134. Dhingra H, Valdivieso M, Tannir N et al. Combined modality treatment for mesothelioma with cytoxan and adriamycin, and DTIC and adjuvant surgery. Proc Am soc Clin Oncol 1983; 2: 205.
135. Samson MK, Wasser LP, Borden EC et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced malignant mesothelioma: A sarcoma intergroup study. J Clin Oncol 1987; 5: 86-91.
136. Lerner H, Schoenfeld DA, Martin A et al. Malignant mesothelioma. The Eastern Cooperative Group (ECOG) experience. Cancer 1983; 52: 1981-5.
137. Krarup-Hansen H. Letters to the Editor (response to ref 116). Lung Cancer 1996; 16: 101-2.
138. Gelfand K, Kang E, Kaiser LR et al. Mesothelioma patients administered recombinant adenoviral-based gene therapy exhibit TH1 cellular immune response. Abstract Int Mesothelioma Interest Group Meeting (IMIG) Philadelphia 1997: 55.
139. Smythe WR, Kaiser LR, Hwang HC et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994; 57: 1395-401.
140. Sterman DH, Albelda SM, Coonrod LE et al. Adenoviral mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy for malignant mesothelioma: Results of a phase I clinical trial. Philadelphia: IMIG 1997; 52 (Abstr).
141. Rizk N, Amin K, Chang M et al. Evaluation of the bystander effect in adenovirus mediated p53 gene therapy. Philadelphia: IMIG 1997; 56 (Abstr).
142. Costanzi J, Darzynkiewicz Z, Chun H et al. The use of Onconase for patients with advanced malignant mesothelioma. Philadelphia: IMIG 1997; 59 (Abstr).
143. Christmas TI, Musk AW and Robinson BWS. Phase II study of recombinant human α-interferon therapy in malignant pleural mesothelioma. Proc Am Assoc Cancer Res 1990; 31: 283.
144. Boutin C, Viallat JR, Van Zandwijk N et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991; 67: 2033-7.
145. Caminschi I, Scott B, Garlepp M, Robinson B. Systemic intratumoral and paracrine delivery of IL-12 prevents or delays the onset of murine malignant mesothelioma. Philadelphia: IMIG 1997; 17 (Abstr).
146. Kang E, Sterman D. Chang M et al. Lack of correlation between stage of mesothelioma and ability to mount an immune response. Philadelphia: IMIG 1997; 18 (Abstr).
147. Marzo AL, Fitzpatrick DR, Scott BM, Robinson BWS. Blockade of tumour derived TGFβ in vivo using antisense oligonucleotides. Philadelphia: IMIG 1997; 19 (Abstr).
148. Middleton GW.Verrill MW, Priest K et al. Good symptom relief with MVP (mitomycin C, vinblastin, cisplatin) chemotherapy in malignant mesothelioma. Proc Am Soc Clin Oncol 1997; 16: 475a.
149. Planting AST, Van der Burg MEL, Goey SH et al. Phase II study of a short course of weekly cisplatin combined with long term oral etoposide in malignant mesothelioma. Ann Oncol 1995; 613-5.
150. Hunt KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant mesothelioma with methotrxate and vinblastin, with or without platinum chemo therapy. Chest 1996; 109: 1239-42.
151. Breau JL, Boaziz C, Morere JJF et al. Combination chemotherapy with cisplatin, Adriamycin, bleomycin and mitomycin C, plus systemic and intrapleural hyaluronidase in 25 consecutive cases of stage II, III pleural mesothelioma. Paris: IMIG 1991; 5 (Abstr).